Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy

Trial Profile

Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs GTx 758 (Primary) ; Antiandrogens
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors GTx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jan 2017 This trial has been completed in Hungary (End date:2016-11-09) as per European Clinical Trials Database record.
    • 10 May 2016 Results of final primary endpoint evaluation from 250 mg GTx-758 cohort of this study (n=39) presented at the 111th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top